Diagnostic codes used to define hospitalisation due to infectious disease
and infant use after birth was adjusted for pregnancy use and maternal use preceding the infant use. b For infant macrolide use days 0 to 13 10 after birth, the exposed case with congenital malformations had registered diagnoses of agenesia, atresia or congenital stenosis of anus with 11 fistula (DQ422) and agenesia, atresia or congenital stenosis of anus without fistula (DQ423). For maternal macrolide use days 0 to 13 after birth, one of the exposed cases was the same as for infant macrolide use and the other exposed case had a registered diagnosis of congenital 7 5 birth order, sex, current age of infant and calendar period; for infant and maternal use after birth: birth order, sex, current age of infant and calendar period, gestational age (ga), being small for 6 gestational age, caesarean section, maternal smoking, congenital malformations diagnosed prior to IHPS. Estimates were additionally adjusted for any preceding macrolide use as follows: maternal 7 use during gestational weeks 0 to 27 was not further adjusted, maternal use gestational weeks 28 to birth was adjusted for any use during gestational weeks 0 to 27, maternal use after birth was 8 adjusted for pregnancy use and for infant use preceding the maternal use and infant use after birth was adjusted for pregnancy use and maternal use preceding the infant use. Assuming that the association reflects a mediating effect of breast feeding, the observed 6 association might be due to no association among non-breastfed infants and an even stronger association among 7 breastfed infants. We do not have information on breast feeding to directly evaluate this, but as breast feeding is 8 a strong risk factor 7 , it is important to evaluate. In the following we therefore evaluate how missing breast 9 feeding information might influence our results by using external information on breast feeding to estimate the 10 association among breastfed and compare this with the observed association for all infants.
Supplementary

11
As the crude rate ratio (RR) (3.80) and the adjusted RR (3.49) are not very different, the evaluation is based on 12 the crude association. There are 11 exposed cases during 1072 person years and 834 unexposed cases during 
14
The unknown number of cases stratified by breast feeding status are termed x00 (unexposed non-breastfed 15 cases), x01 (unexposed breastfed cases), x10 (exposed non-breastfed cases), x11 (exposed breastfed cases) and
16
similarly T00,T01,T10 and T11 for person years.
For simplicity we assume that a proportion p of the infants are breast fed throughout follow-up. We estimate
18
person years among exposed and unexposed breastfed, T11 and T01, as pT1* and pT0*. We estimate the number of 19 cases among exposed and unexposed breastfed, x11 and x01, as x1*-r00(1-p)T1* and x0*-r00(1-p)T0*, with roo as the 20 rate among unexposed non-breastfed, i.e. the number of cases among breastfed are estimated as the total 21 number of cases minus the expected number among non-breastfed within exposed and unexposed, respectively.
roo is estimated using r00(pRRbreastfed+(1-p))=r0, with RRbreastfed as the rate ratio of IHPS by breast feeding status and 23 r0 as the rate among unexposed that is estimated by (x0*/T0*), i.e. r00 is estimated by (x0*/T0*)/ (pRRbreastfed+ (1-p) ).
24
We estimate RR=(x11/T11)/(x01/T01) for maternal use during days 0 to 13 after birth compared with no use among 
31
The small number of cases exposed to maternal use 14-120 days after birth do not allow for the same analysis
32
within the investigated range of breast feeding proportions. However, we find it fair to assume that an
